The EHR Is Becoming Programmatic Media. Pharma Buyers Should Pay Attention.

For years, pharmaceutical marketers have treated point-of-care media as something adjacent to the broader digital advertising ecosystem.

Display, connected TV, online video, paid social, and other channels might flow through familiar programmatic buying infrastructure. Electronic health record (EHR) placements, meanwhile, often lived in a different operational category—purchased through specialized healthcare vendors, direct relationships, or managed-service programs built around the unique requirements of clinical environments.

That boundary is starting to weaken.

OptimizeRx recently announced an integration with The Trade Desk’s OpenPath that is expected to make authenticated point-of-care inventory across more than 400 EHR and e-prescribing systems directly accessible to advertisers using The Trade Desk. OptimizeRx says the network reaches approximately 800,000 verified healthcare professionals. The inventory is expected to become available through OpenPath in the fourth quarter of 2026.

The development is more significant than another source of HCP inventory being added to a demand-side platform.

It points toward a future in which programmatic point-of-care advertising becomes increasingly connected to the same buying infrastructure pharma marketers already use for the rest of their digital media.

And that could change far more than how an impression gets purchased.

Table of Contents

• Why Point-of-Care Media Has Historically Been Different
• What the OptimizeRx and OpenPath Integration Changes
• EHR Inventory Could Become Part of the Broader Media Plan
• Media Planning May Need a New Definition of “Channel”
• Buying Efficiency Is Only Part of the Story
• Measurement Could Become More Complicated
• Agency Responsibilities May Start to Blur
• Clinical Context Still Makes EHR Media Different
• What Pharma Buyers Should Be Asking Now
• The Bigger Shift: From Specialty Channel to Media Infrastructure
• Frequently Asked Questions

Why Point-of-Care Media Has Historically Been Different

The attraction of EHR advertising has always been context.

A physician reading an article online may be professionally relevant to a pharma campaign, but a physician working inside an EHR is doing something fundamentally different. The clinician may be reviewing a chart, considering treatment options, preparing a prescription, or completing another task directly connected to patient care.

That proximity to clinical decision-making is what gives point-of-care inventory its distinctive value.

Historically, however, accessing that environment has not looked much like conventional programmatic advertising. EHR inventory has typically been purchased through direct managed-service relationships or specialized healthcare platforms, making it harder to integrate into broader omnichannel programs.

That separation made sense. Clinical-workflow media has specialized technology, privacy, compliance, contextual, and measurement considerations that ordinary digital display does not necessarily share.

But it also created organizational silos.

A pharma company could have one team planning HCP programmatic media and another managing point-of-care activation, even when both were ultimately trying to influence engagement among overlapping groups of healthcare professionals.

What the OptimizeRx and OpenPath Integration Changes

OpenPath was created by The Trade Desk to give advertisers a more direct connection to participating advertising inventory. The platform is designed to simplify access to inventory and reduce unnecessary complexity in the programmatic supply path.

Adding EHR inventory to that infrastructure creates an interesting convergence.

Through the announced integration, advertisers using The Trade Desk are expected to gain access to OptimizeRx inventory spanning more than 400 EHR and e-prescribing systems and roughly 800,000 verified HCPs.

Instead of necessarily treating EHR engagement as a completely separate media purchase, a pharma advertiser could increasingly incorporate those opportunities into the technological environment already supporting other portions of its media strategy.

That does not suddenly make an EHR placement interchangeable with a banner ad on a general medical website.

It does, however, begin making them more operationally connected.

EHR Inventory Could Become Part of the Broader Media Plan

That distinction matters.

Programmatic buying has spent years breaking down boundaries between media formats. Display, video, audio, connected TV, digital out-of-home, and other inventory can increasingly be planned through interconnected platforms even though the consumer experience of each format remains different.

Healthcare may now be seeing a similar transition.

Programmatic access to point-of-care inventory could allow clinical-workflow placements to sit alongside a brand’s other HCP media investments rather than being planned after the “main” digital media budget has already been allocated.

That potentially changes the planning conversation.

Instead of asking:

“How much should we spend on point of care?”

teams may increasingly ask:

“At which moments across the HCP journey should this audience be reached?”

An HCP could encounter educational content on a professional site, a video elsewhere on the open internet, and an appropriate brand message within a clinical workflow. The strategic question becomes how those exposures work together rather than which vendor or channel receives a predetermined portion of the budget.

Media Planning May Need a New Definition of “Channel”

Healthcare media plans have traditionally been organized around channels and vendors partly because that is how inventory was bought.

But buying infrastructure shapes strategy more than marketers sometimes acknowledge.

If EHR media becomes easier to activate alongside other HCP media, planners may begin organizing campaigns less around individual channels and more around audiences, contexts, and decision moments.

Point of care would still remain a distinct environment. Yet operationally, it could become another available activation opportunity within a broader HCP media architecture.

That could also make budget allocation more fluid.

A planner seeing strong performance from authenticated HCP inventory could potentially shift investment toward point-of-care placements without creating an entirely separate procurement and activation process.

Conversely, clinical-workflow media would have to compete more visibly against other HCP investments for budget.

Greater accessibility does not guarantee greater spending. It may instead bring point-of-care inventory into a more direct performance comparison with the rest of the media plan.

Buying Efficiency Is Only Part of the Story

It would be easy to interpret the OptimizeRx announcement primarily as a supply-path story.

There is certainly an efficiency argument.

OpenPath is designed to provide more direct access to participating inventory, and The Trade Desk has positioned supply-path optimization as a way to reduce unnecessary routes between buyers and advertising opportunities.

For pharma advertisers, however, the larger consequence may be workflow consolidation.

When specialized inventory can be accessed through technology already used by agencies and brands, buyers may gain more consistency in campaign setup, budget management, reporting, and optimization.

The result could be fewer artificial boundaries between what has historically been considered “digital media” and what has been considered “clinical engagement.”

But consolidation also raises harder questions.

Measurement Could Become More Complicated

Putting different types of inventory into the same buying environment can make them easier to compare.

It can also encourage comparisons that should not be made.

An EHR exposure occurring close to a prescribing decision carries a different context from an HCP seeing an ad while reading general medical news. A standard impression-level comparison may therefore miss the strategic value of where the exposure occurred.

Pharma marketers will need to avoid allowing technological consolidation to flatten meaningful contextual differences.

Measurement frameworks may need to distinguish between metrics that can legitimately be standardized across channels and outcomes that depend heavily on the environment.

Reach, frequency, delivery, and cost may become easier to view together.

Clinical relevance, prescribing impact, treatment behavior, or downstream patient outcomes require a much more careful methodology.

The growing convergence of programmatic media and point-of-care advertising therefore creates a measurement challenge as much as a buying opportunity: marketers need unified reporting without pretending every impression is equivalent.

Agency Responsibilities May Start to Blur

The change could also affect how pharma agencies divide responsibilities.

Point-of-care programs have traditionally involved specialized teams or partners with expertise in healthcare workflows. Programmatic media may be managed by another trading or activation function. Analytics could sit somewhere else again.

What happens when the same campaign increasingly touches all three?

Someone still needs to understand the clinical context of the placement. Someone needs to manage the programmatic buying infrastructure. Someone needs to ensure audience strategy, creative requirements, measurement design, privacy standards, and regulatory review remain aligned.

That creates a potential ownership question.

The answer is unlikely to be that traditional programmatic traders simply absorb point of care as another line item.

A more plausible evolution is greater collaboration between programmatic, HCP strategy, point-of-care, analytics, medical, legal, privacy, and regulatory functions.

The technology may converge faster than agency organizational charts do.

Clinical Context Still Makes EHR Media Different

This is perhaps the most important caution.

Making EHR inventory programmatically accessible does not transform the EHR into an ordinary media environment.

It remains part of a clinical workflow.

That means message relevance, interruption, timing, privacy, data use, frequency, and creative execution deserve different scrutiny than they might in many consumer advertising environments.

OptimizeRx describes its network in terms of authenticated HCP reach and proximity to treatment decisions—characteristics that make the inventory attractive precisely because it is not ordinary display inventory.

Pharma marketers should therefore resist confusing easier buying with commoditization.

The technical pipes may increasingly resemble mainstream programmatic media. The strategic responsibility attached to an impression inside a physician’s workflow remains considerably different.

What Pharma Buyers Should Be Asking Now

Even brands that are not ready to activate through this particular integration should pay attention to what it represents.

Media teams should start asking whether their existing planning frameworks are prepared for point-of-care inventory to become more programmatically accessible.

Questions worth examining include:

Who owns the budget? If point-of-care media becomes available through mainstream programmatic infrastructure, does the investment sit with the HCP team, programmatic team, omnichannel team, or a shared budget?

How should frequency be managed? If the same authenticated HCP is reachable in clinical and nonclinical environments, brands need to consider the overall exposure strategy rather than optimizing each channel independently.

Which metrics should be unified? Common buying infrastructure may create more consolidated reporting, but teams still need to decide which comparisons are meaningful.

Where does specialized expertise remain necessary? Easier technical access should not eliminate the need for people who understand EHR workflows and healthcare-specific requirements.

How will creative strategy differ? Messaging appropriate during general professional media consumption may not be appropriate at a clinical decision point.

How should the agency model evolve? Brands may need clearer responsibility matrices as programmatic trading and point-of-care expertise increasingly overlap.

The Bigger Shift: From Specialty Channel to Media Infrastructure

The most consequential part of the OptimizeRx and The Trade Desk development may not be the individual inventory being made available.

It is what the integration says about the direction of healthcare advertising.

OptimizeRx had already announced in May 2026 that it was creating programmatic connection points between its EHR network and demand-side platforms. The OpenPath announcement takes that strategy further by connecting point-of-care inventory to one of the major infrastructures used for broader programmatic media buying.

That suggests point of care may be moving from a specialized destination on the media plan toward something embedded within the larger buying ecosystem.

If that continues, the distinction between “HCP media” and “point-of-care media” may become less useful operationally.

The more relevant distinction could eventually be between the contexts in which an HCP is reached: browsing, researching, learning, watching, or actively treating a patient.

That would represent a meaningful evolution in pharma media strategy.

The EHR is not becoming just another website with ad inventory. But the infrastructure used to buy media inside it is beginning to look considerably more familiar.

And for pharma buyers, that may be the development worth watching most closely.

Frequently Asked Questions

What is programmatic point-of-care advertising?

It refers to using programmatic technology to buy point-of-care media within healthcare environments such as EHR and e-prescribing workflows. It combines aspects of automated digital media buying with inventory designed to reach healthcare professionals near clinical decision moments.

What did OptimizeRx announce with The Trade Desk?

OptimizeRx announced on September 22, 2026, that its authenticated point-of-care inventory would be integrated with The Trade Desk’s OpenPath. The company says the integration will provide access to inventory across more than 400 EHR and e-prescribing systems reaching approximately 800,000 verified HCPs. Availability through OpenPath is expected in Q4 2026.

Does programmatic access make EHR advertising the same as regular digital display?

No. The buying infrastructure may become more closely connected, but EHR advertising operates within a clinical environment. Context, workflow relevance, privacy considerations, creative requirements, measurement, and compliance can make point-of-care placements fundamentally different from ordinary digital advertising.

Why does this matter for pharma media agencies?

As EHR inventory becomes accessible through platforms already used for broader media buying, responsibilities traditionally divided among programmatic, HCP, point-of-care, analytics, and omnichannel teams may increasingly overlap. Agencies may need new workflows for planning, measurement, optimization, and governance across those functions.

Could programmatic point-of-care advertising change pharma media planning?

Potentially. Easier access to point-of-care inventory could encourage brands to plan around HCP audiences and decision moments rather than treating EHR placements as an isolated specialty channel. The challenge will be integrating the buying process without losing the clinical context that makes the inventory distinctive.